Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anastrozole
- Development stage
- Approved
- Lead developer
- AstraZeneca
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Anastrozole is a nonsteroidal aromatase inhibitor used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It works by inhibiting the enzyme aromatase, which is responsible for converting androgens to estrogens, thereby reducing estrogen levels in the body. This reduction slows or stops the growth of estrogen-dependent breast cancer cells. Anastrozole is also used as a first-line treatment for advanced or metastatic breast cancer and can be prescribed to prevent breast cancer in women at high risk. The drug is taken orally as a 1 mg tablet once daily[1][2][3][4][5][6].
- Brand names
- Arimidex
- Other names
- 阿那曲唑
02
Targets
CYP19A1 (Aromatase)
Beyond the preview
Go deeper on anastrozole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anastrozole.